Crude Oil Drops Over 2%; Akouos Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 300 points on Tuesday.
Nasdaq Rises Over 100 Points; Goldman Sachs Tops Q3 Views
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Tuesday.
Health Care Company Eli Lilly Announces Acquisition of Akouos
Eli Lilly (NYSE:LLY) has announced an acquisition of Akouos (NASDAQ:AKUS) that is expected to be completed in Q4 of 2022.
Lilly To Acquire Akouos; Acquisition Valued At $487M Plus Contingent Value Right For Aggregate Amount Of $610M
Proposed acquisition will accelerate gene therapies that aim to restore, improve, and preserve hearing for patients living with disabling hearing loss worldwide
Transaction valued at approximately $487 million plus a
Eli Lilly Whale Trades For October 17
A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly.
Looking at options history for Eli Lilly (NYSE:LLY) we detected 10 strange trades.
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Analyst Upgrades Biogen Citing Upcoming Conference, Competitive Readouts
Stifel upgraded Biogen Inc (NASDAQ: BIIB) from Hold to Buy, saying shares have faded since positive lecanemab data in mild Alzheimer's.
Bankrupt Zosano Sells Its Drug Delivery Tech That Once Partnered With Pharma Giants
Emergex Vaccines Holding Limited acquired the assets of Zosano Pharma Corporation. The sale was part of the customary proceedings after…
Morgan Stanley Maintains Overweight on Eli Lilly, Lowers Price Target to $408
Morgan Stanley analyst Terence Flynn maintains Eli Lilly (NYSE:LLY) with a Overweight and lowers the price target from $412 to $408.
FDA Highlights Quality Check Issues At Eli Lilly’s New Jersey Manufacturing Site
An inspection in July by the FDA revealed several issues surrounding quality control at Eli Lilly And Co's (NYSE: LLY) manufacturing site in Branchburg, NJ.